title: Spinal estrogen receptor alpha mediates estradiol-induced pronociception in a visceral pain model in the rat.
abstract: We previously reported that 17β-estradiol (E2) is pronociceptive in a visceral pain model in the rat. Subcutaneously (s.c.) administered E2 reversed the decrease in the colorectal distention (CRD)-evoked visceromotor response produced by ovariectomy (OVx) and CRD-induced nociceptive responses were greater in proestrous rats compared with met/diestrous rats. The site of action, the type of estrogen receptors activated, and the possible intracellular signaling pathway involved are yet to be established. In the present study, intrathecal (i.t.) E2 administered to OVx rats mimicked the effects of s.c. E2, suggesting that spinal estrogen receptors are involved. This is further supported by the observations that the anti-estrogen ICI 182,780 injected i.t. in intact female rats significantly decreased the visceromotor response to CRD, the response of colonic afferents was not affected by OVx, and colonic afferents did not label for estrogen receptor α (ERα). The ERα selective agonist, 4,4',4''-[4-propyl-(1H)-pyrazole-1,3,5-triyl]tris-phenol (PPT; s.c. or i.t.) facilitated the visceromotor response similar to E2, suggesting ERα activation is involved in mediating the pronociceptive effect of E2. PPT (s.c. or i.t.) increased the response of spinal dorsal horn neurons to CRD, indicating a spinal site of action. In addition, s.c. E2 or PPT increased CRD-induced spinal extracellular signal-regulated kinase (ERK) phosphorylation that was not observed in OVx rats and a mitogen-activated protein kinase (MAPK) kinase (MEK) inhibitor blocked facilitation of the visceromotor response by PPT. Taken together, the present study demonstrates that spinal ERα mediates the pronociceptive effect of E2 on visceral signal processing through activation of the MAPK pathway.
authors.affiliation: Department of Neural and Pain Sciences, University of Maryland Dental School, Baltimore, MD, USA.
authors.forename: Yaping
authors.initials: Y
authors.lastname: Ji
authors.forename: Bin
authors.initials: B
authors.lastname: Tang
authors.forename: Richard J
authors.initials: RJ
authors.lastname: Traub
mesh_terms: D000344:Afferent Pathways / Q000502:physiology; D000704:Analysis of Variance; D000818:Animals; D003106:Colon / Q000294:innervation; D004195:Disease Models, Animal; D004791:Enzyme Inhibitors / Q000494:pharmacology; D004958:Estradiol / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use; D004965:Estrogen Antagonists / Q000627:therapeutic use; D047628:Estrogen Receptor alpha / Q000378:metabolism*; D004967:Estrogens / Q000009:adverse effects; D048049:Extracellular Signal-Regulated MAP Kinases / Q000378:metabolism; D005260:Female; D000077267:Fulvestrant; D036145:Ginsenosides / Q000009:adverse effects; D010052:Ovariectomy; D010146:Pain / Q000188:drug therapy / Q000209:etiology* / Q000378:metabolism / Q000473:pathology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D012502:Sapogenins / Q000009:adverse effects; D013116:Spinal Cord / Q000378:metabolism*; D014781:Viscera / Q000294:innervation* / Q000378:metabolism*
chemical_list: D004791:Enzyme Inhibitors; D004965:Estrogen Antagonists; D047628:Estrogen Receptor alpha; D004967:Estrogens; D036145:Ginsenosides; D012502:Sapogenins; C507965:ginsenoside 20S-protopanaxatriol; D000077267:Fulvestrant; D004958:Estradiol; D048049:Extracellular Signal-Regulated MAP Kinases